

3.2.2. *Number of books and chapters in edited volumes/books published and papers published in national/ international conference proceedings per teacher during the year*


QnM 3.2.2.1. Total number of books and chapters in edited volumes/books published and papers in national/ international conference proceedings during the year

Year	2022 - 23
Number	04



DIRECTOR CUM PRINCIPAL  
LAUREATE INSTITUTE OF  
PHARMACY KATHOG  
TEH. JAWALAMUKHI  
DISTT. KANGRA (H.P.)

3.2.2 Number of Books and Chapters in edited volumes/ books published, and Papers in National/International conference-proceeding per Teacher during last five years							
Sr.No	Name of Teacher	Title of book/Chapter published	Title of Paper	Year of Publications	ISBN/ISSN number	Weather at the time of publication affiliating institute was same (yes/ No)	Name of Publisher
1	Mr. Shiv kumar Kushawaha	Pharmaceutical Microbiology	Pharmaceutical Microbiology	2023	978-81-964343-9-7	Yes	Gyan Publications
2.	Dr. Shammy Jindal	Product development and scale up challenges in cancer vaccine development	Product development and scale up challenges in cancer vaccine development	2022	978-0-12-823686-4	yes	Academic Press India
3.	Dr. Shammy Jindal	Regulatory landscape in the approval of cancer vaccine	Regulatory landscape in the approval of cancer vaccine	2022	978-0-12-823686-4	Yes	Academic Press India
4.	Dr. Shammy Jindal	Progress of cancer Nano medicine, Clinical Hurdles and Opportunities	Progress of cancer Nano medicine, Clinical Hurdles and Opportunities	2022	978-981-19-5558-7	Yes	Springer Nature Singapur

  
 DIRECTOR CUM PRINCIPAL  
 LAUREATE INSTITUTE OF  
 PHARMACY KATHOG  
 TEH. JAWALAMUKHI  
 DISTT. KANGRA (H.P.)

**According to the New Syllabus**  
as prescribed by : Pharmacy Council of India

# Pharmaceutical Microbiology

*For the Students of*

**B. PHARM THIRD SEMESTER**

*Written by :* 

**Sandhya Yadav**

*M. Pharm, Ph.D.\**

*Assistant Professor*

Tahira Institute of Medical Sciences,  
GIDA, Gorakhpur (U.P.)

**Ajeet Kumar Singh**

*M. Pharm, Ph.D.\**

*Associate Professor*

Tahira Institute of Medical Sciences,  
GIDA, Gorakhpur (U.P.)

**Dr. Kapil Kumar Verma**

*M. Pharm, Ph.D.*

*Professor & Principal*

Minerva College of Pharmacy,  
Indora, Kangra (H.P.)

**Shiv Kumar Kushawaha**

*M. Pharm, Ph.D.\**

*Associate Professor & Head*

Department of Pharmacology,  
Laureate Institute of Pharmacy,  
Kathog, Jawalaji, Kangra (H.P.)



## Gyan Publications

E-11, Janak Puri, Garh Road, Meerut-250004 (U.P.)  
Contact : 7895144449, 7895244449

DIRECTOR  
LAUREATE INSTITUTE OF  
PHARMACY KATHOG  
TEH. JAWALAJI  
DISTT. KANGRA

ISBN No - 978-981-19-5558-7

Publisher - Springer Nature Singapore.



## Progress of Cancer Nano Medicine, Clinical Hurdles, and Opportunities

3

Priti Tagde, Anshul Sharma, Kamyra Goyal, and Shammy Jindal

### Abstract

Cancer is the second leading cause of mortality in the globe. One of the most severe flaws in most anticancer medicines is their lack of tumor selectivity. Nanomedicine for cancer treatment given intravenously to avoid renal clearance cannot pass through tight endothelial junctions in normal blood arteries and accumulate in plasma at high levels. In this chapter, we will look at the advancements of nanomedicine in all areas of pharmaceuticals. We will also discuss the challenges encountered during clinical testing and development of cancer medicines, as well as future opportunities.

### Keywords

Cancer · Nanomedicine · Clinical hurdles · Chemotherapy · EPR effect

P. Tagde

Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, India

A. Sharma

Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, India


Department of Pharmaceutical Sciences, Laureate Institute of Pharmacy, Kathog, India

K. Goyal

Department of Pharmaceutical Chemistry, GHG Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, India

S. Jindal (✉)

Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, India

  
DIRECTOR CURRICULUM  
LAUREATE INSTITUTE OF  
PHARMACY KATHOG  
TEH. JAWAHAR MUKHI  
DISTT. KANGRA (H.P.)

© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2022

M. Rahman et al. (eds.), *Hormone Related Cancer Mechanistic and Nanomedicines*, [https://doi.org/10.1007/978-981-19-5558-7\\_3](https://doi.org/10.1007/978-981-19-5558-7_3)



ScienceDirect

## Nanotherapeutics in Cancer Vaccination and Challenges

2022, Pages 325-348

## Chapter 17 - Regulatory landscape in the approval of cancer vaccine

Kamya Goyal<sup>1</sup>, Bharti Mangla<sup>2</sup>, Navdeep Singh<sup>3</sup>, Honey Goel<sup>4</sup>, Kunal Goyal<sup>5</sup>, Shammy Jindal<sup>3</sup>,  
Mohammad Javed Ansari<sup>6</sup>, Waleed H. Almalki<sup>7</sup>

Show more ▾

☰ Outline | 🔊 Share 📄 Cite

<https://doi.org/10.1016/B978-0-12-823686-4.00001-X>

Get rights and content

## Abstract

Cancer is a fatal disease that affects a large number of people. Some cancers are difficult to treat with traditional methods such as surgery, radiation, and chemotherapy, but they can be managed with cancer vaccines, which stimulate the body's immune response. The development of therapeutic vaccinations has been difficult, with only one recent success. However, because our understanding of cancer immunology has advanced significantly in recent years, there is great hope for the development of effective therapeutic vaccines. This chapter focuses on identifying key regulatory and developmental challenges in the field of cancer immunotherapy. The regulatory framework for cancer vaccines in the European Union, the United States, Japan, and certain developing nations is described. In addition, the study addresses several specific concerns about the design and conduct of cancer vaccine clinical trials.


< Previous

Next >

## Keywords

Cancer vaccine; Cervarix; Immunotherapy; Product development; Regulations

Recommended articles

  
 DIRECTOR CUM PRINCIPAL  
 LAUREATE INSTITUTE OF  
 PHARMACY KATHOG  
 JEH. JAWALAMUKHI  
 DISTT. KANGRA (H.P.)



## Nanotherapeutics in Cancer Vaccination and Challenges

2022, Pages 313-324

### Chapter 16 - Product development and scale-up challenges in cancer vaccine development

Bharti Mangla<sup>1</sup>, Pankaj Kumar<sup>2</sup>, Kamya Goyal<sup>3</sup>, Kanchan Kohli<sup>1</sup>, Shammy Jindal<sup>4</sup>

Show more

Outline | Share Cite

<https://doi.org/10.1016/B978-0-12-823686-4.00021-5>

Get rights and content

#### Abstract

Since the 1950s, curing cancer with vaccines has been a difficult research field. Across the years, various novel approaches have been created due to the lack of appropriate active immunotherapies. Indeed, the use of vaccines against the cancer could be on the edge of being an effective strategy. Cancer vaccines include excellent sensitivity and moderate toxicity, and they have potential for a lifelong impact in immunologic memory care. This study focuses on emerging approaches used in recent therapeutic cancer vaccine clinical trials, recognizing the potential of cancer vaccines, evaluating the current state of the production of cancer vaccines, and recommending directions for future studies. In addition, we discuss concerns related to various types of tumor vaccines and include guidelines for characterizing such vaccines at different stages of development.

Previous

Next

#### Keywords

Antigen discovery; Cancer; Product development; Scale-up; Vaccines

\* Recommended articles

DIRECTOR CUM PRINCIPAL  
 LAUREATE INSTITUTE OF  
 PHARMACY KATHOG  
 TEH. JAWALAMUKHI  
 DISTT. KANGRA (HP)